SABCS 2022 | Impact of race on clinical, socioeconomic, genomic characteristics among patients with MBC

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, discusses a retrospective study on the impact of race on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with metastatic breast cancer. atient demographics and clinical trial enrollmen were determined by retrospective data collection. There were no significant differences in median age at diagnosis, disease subtype distribution, proportions of de-novo/recurrent metastatic breast cancer, presence of visceral metastases, Charleston comorbidity index, menopausal status, and level of education across racial groups. Median distance traveled to the institution also varied based on race, with White patients traveling further (White: 39.1 miles, Black: 21.8 miles, Hispanic 9.4 miles, Asian 9.1 miles. In addition, type of insurance varied based on race, with White patients having the highest rates of commercial insurance and Medicare, Black patients having the highest rate of state-supported insurance, and Asian patients having the highest uninsured rates. Overall, significant race-based differences in non-English speaking status, insurance type, and median distance traveled to the institution. Racial/ethnic minority patients were less likely to receive genotype-matched therapy than White patients. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.